Navigation Links
Key leukemia defense mechanism discovered by VCU Massey Cancer Center
Date:9/30/2010

Richmond, Va. (September 30, 2010) Virginia Commonwealth University Massey Cancer Center researcher Steven Grant, M.D., and a team of VCU Massey researchers have uncovered the mechanism by which leukemia cells trigger a protective response when exposed to a class of cancer-killing agents known as histone deacetylase inhibitors (HDACIs). The findings, published in the Journal of Biological Chemistry, could lead to more effective treatments in patients with leukemia and other cancers of the blood.

"Our findings provide new insights into the ways such cancer cells develop resistance to and survive treatment," says Grant, associate director for translational research and professor of medicine. "This knowledge will now allow us to focus our efforts on strategies designed to prevent these self-protective responses, potentially rendering the cancer cell incapable of defense and increasing the effectiveness of therapy."

The discovery centers on modification of a protein known as NEMO. Researchers have known for some time that HDACIs trigger a protective response in leukemia cells by activating a survival signaling pathway known as NF-κB, which limits the ability of HDACIs to initiate a cancer cell suicide program known as apoptosis. However, it was previously thought this process occurred through activation of receptors residing on the cancer cell surface. What VCU Massey researchers discovered was that HDACIs initially induce DNA damage within the cell nucleus, leading to modification of the NEMO protein, which then triggers the cytoprotective NF-κB pathway. By disrupting modifications of the NEMO protein, NF-κB activation can be prevented, and as a consequence, the cancer-killing capacity of HDACIs increases dramatically.

HDACIs represent an approved form of treatment for certain forms of lymphoma, and VCU Massey Cancer Center has been working for over seven years to develop strategies designed to improve their effectiveness in leukemia and other blood cancers. Grant's team is now focusing on ways to capitalize on this discovery by designing strategies that interrupt NEMO modifications through the use of pharmacologic agents and other means.

"Our goal is to move these findings from the laboratory to the bedside as quickly as we possibly can. There are currently several drugs in early stages of development that hold promise in disrupting the NEMO-related NF-κB pathway, but further research defining their safety and effectiveness will be required before we can incorporate them into new therapies," says Grant.


'/>"/>

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Researcher at Childrens Hospital LA discovers way to overcome radiation resistance in leukemia
2. Experimental Leukemia Drug Proves a Slam Dunk
3. New driver of T cell leukemia growth
4. Targeted agent shows promise for chronic lymphoid leukemia
5. Technique to preserve fertility in young women may be unsafe for patients with leukemia
6. UCSF-led team discovers familial link in rare childhood leukemia
7. Research consortium at CHLA receives $410,000 to study leukemia and lymphoma
8. Stem cell transplantation of therapy-resistant chronic leukemia successful
9. Combination therapy targets stubborn leukemia stem cells
10. Gene loss causes leukemia
11. Genetic Pattern May Predict Leukemia Relapse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... An educational campaign ... inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It also provides ... associations and industry leaders such as Bioness. , As patients feel increasingly ...
(Date:5/27/2016)... ... 2016 , ... Aimed at nurses and employees in the health care world, ... in the nursing and health care industry. It also provides insight to the developing ... , As the nursing industry is coming out of one of the biggest ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... There are ... Hot Dog and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off ... 63 percent say grilling is their favorite way to cook a hot dog, far ...
(Date:5/26/2016)... ... 2016 , ... Georgia State University College of Law is ... Answering to the increasing demand for curricular specializations, the Certificate in Intellectual Property ... land use law. ,  , “The demand for lawyers with specific knowledge in ...
(Date:5/26/2016)... ... 2016 , ... Cardiac arrhythmia is a common complication following ... survival, reports a team of UPMC researchers in the largest study of its ... Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead to better ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... -- The healthcare sector is large and ... falling under its umbrella.  A rather overlooked sector are ... about, these healthcare companies are still trying to prove ... by far the largest consumer of the healthcare market ... Nutranomics Inc. (OTC: NNRX), KollagenX Corp. (OTCQB: KGNX), Bioelectronics ...
(Date:5/26/2016)... -- TARE (Transarterial Radio-embolization) Using Yttrium-90 ... Overall Decreased Use of Hospital Resource ... healthcare company, has today announced the publication of ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research), ... yttrium-90 glass microspheres is associated with cost savings ...
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
Breaking Medicine Technology: